A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC).

Joseph, Mathew J.; Barnes, Kirk; Blachly, Ronald; Kuzur, Michel E.; Bendell, Johanna C.

doi:10.1200/jco.2015.33.15_suppl.e14673

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in a phase II study of second-line axitinib or bevacizumab with mFOLFOX6 or FOLFIRI, axitinib did not improve outcomes versus bevacizumab plus chemotherapy and was less well tolerated [Bendell et al 2013]. Initial data suggest maintenance axitinib may be effective after first-line mFOLFOX plus bevacizumab for mCRC [Joseph et al 2015].…”

Section: Other Antiangiogenic Agents For Refractory Metastatic Colorementioning

confidence: 99%

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

Riechelmann

Grothey

2016

Ther Adv Med Oncol

View full text Add to dashboard Cite

Even though significant improvements in the treatment of colorectal cancer (CRC) have been made in recent years, survival rates for metastatic colorectal cancer (mCRC) are poor. Effective treatment options for metastatic colorectal cancer remain limited, and new therapeutic strategies are desperately needed. Several tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) that target angiogenesis, a critical process for facilitating tumor cell growth, invasion, and metastasis, are either approved or in clinical development for the treatment of mCRC. Many of these agents have shown efficacy in mCRC, both as single agents and in combination with standard chemotherapy regimens. However, there is a need for predictive markers of response to identify those patients most likely to benefit from antiangiogenic therapy, and, to date, no markers of this type have been validated in patients. Additionally, because antiangiogenic agents typically cause cytostatic as opposed to cytotoxic antitumor effects, it is important to determine the best strategies for evaluating therapeutic response in mCRC to ensure maximum clinical benefit. In this review, we summarize the efficacy and tolerability of approved and investigational antiangiogenic agents for the treatment of mCRC. We also discuss potential markers of response to antiangiogenic agents and how these markers, along with appropriate endpoint selection, can improve clinical trial design.

show abstract

Section: Other Antiangiogenic Agents For Refractory Metastatic Colorementioning

confidence: 99%

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

Riechelmann

Grothey

2016

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC).

Cited by 1 publication

References 0 publications

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

Contact Info

Product

Resources

About